« Previous Next » The Journal of Pediatrics
Volume 152, Issue 3 , Pages 394-399.e2 , March 2008

Modafinil Improves Symptoms of Attention-Deficit/Hyperactivity Disorder across Subtypes in Children and Adolescents

Joseph Biederman, MD
- From the Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA
- Dr Biederman receives research support from the following sources: Shire, Eli Lilly, Pfizer, McNeil, Abbott, Bristol-Myers-Squibb, New River Pharmaceuticals, Cephalon, Janssen, Neurosearch, Stanley Medical Institute, Novartis, Lilly Foundation, Prechter Foundation, National Institutes of Mental Health, National Institute of Child Health and Human Development, and National Institute on Drug Abuse. Dr Biederman is a speaker for the following speakers’ bureaus: Shire, Lilly, McNeil, Cephalon, UCB Pharma, and Novartis. Dr Biederman is on the advisory board of the following pharmaceutical companies: Eli Lilly, Shire, McNeil, Janssen, Novartis, and Cephalon.
- Reprint requests: Joseph Biederman, MD, Massachusetts General Hospital, Pediatric Psychopharmacology Unit, Yawkey Center for Outpatient Care, YAW-6A-6900, 32 Fruit St., Boston, MA 02114.
Steven R. Pliszka, MD
- University of Texas Health Science Center, San Antonio, TX.
- Dr Pliszka receives research support from Eli Lilly and Cephalon and is a speaker for speakers’ bureaus sponsored by Shire and McNeil.